Dr. George Chen is an accomplished pharmaceutical R&D executive with integrity, entrepreneurial spirit, and solid leadership skill. He brings in over 12 years of experience in clinical development, medical affairs, strategic planning and business development. Prior to joining AstraZeneca, Dr. Chen was the Chief Medical Officer at BeiGene, a China based biotech focusing on oncology drug research and development.
Dr. Chen started his pharmaceutical industry career with Eli Lilly, where he served as a Strategy Advisor for Corporate Strategic Assets Management and Business Development and as a Global Medical Advisor for Global Oncology Platform Team. After his tenure at Eli Lilly, Dr. Chen joined GSK as the Chief Medical Officer for Great China Area responsible for clinical development, medical affairs and China portfolio management, and as a global Medicine Development Leader (MDL) with GSK Global Oncology. Later on, he served as a VP/Head of Compound Development Teams for Asia with JnJ Pharmaceutical R&D (JJPRD), and as a VP/Head of North Asia Biotech for Sanofi Oncology. Dr. Chen has deep experience and knowledge in drug development with a proven track record of building high performance development teams and getting CTA and NDA approvals.
Prior to his career in pharmaceutical industry, Dr. Chen was a Senior Staff Scientist and Investigator at NIH in Bethesda of Maryland. Dr Chen received his medical degree from Shanghai First Medical College of Fudan University and his MBA from the Wharton School of University of Pennsylvania. He had his post graduate medical training in oncology at Shanghai Cancer Hospital and New York Medical College, respectively. Dr. Chen is also well published in international peer reviewed journals on oncology and immunology.